Switzerland Archives

News and Trends 22 Sep 2022

Swiss scientists reduce resistance of dormant melanoma cells

Small-molecule targeted therapies revolutionized the treatment of metastatic melanoma, provided that the tumors carry the mutations to respond to these treatments. However, despite an initial response that can be seen in a majority of patients, most of them will undergo relapse even after sometimes spectacular initial responses. These relapses are due to “dormant” persistent cells, […]

September 22, 2022 - 4 minutesmins - By Jim Cornall

News and Trends 20 Sep 2022

ten23 health completes superstructure of new sterile production facility

ten23 health, a global contract development and manufacturing organization (CDMO) has completed the superstructure of its new sterile manufacturing facility. The existing facility of ten23 health’s swissfillon AG company in Visp already offers sterile manufacturing of pre-filled syringes, vials, and cartridges for clinical trial and commercial supplies, in collaboration with ten23 health’s development center in […]

September 20, 2022 - 2 minutesmins - By Jim Cornall

glioblastoma oncolytic virus transgene 2

News and Trends 20 Sep 2022

Collaboration to develop new glioblastoma combination therapy nets €1.06M

Dutch biotech CimCure B.V., French biotech company Covalab, Amsterdam UMC (The Netherlands) and the University of Zurich (Switzerland), have received a €1.06M ($1.08M) grant from EUREKA Eurostars. With a total budget of €2.24M ($2.28M), including investments from the partners, the project aims to develop a new treatment against glioblastoma. CimCure is the lead coordinator of […]

September 20, 2022 - 4 minutesmins - By Jim Cornall

News and Trends 19 Sep 2022

GENFIT to acquire Versantis to expand liver disease portfolio

GENFIT has entered into an exclusivity agreement with a view to acquire all the share capital and voting rights of Versantis, a private Swiss-based clinical stage biotechnology company focused on addressing the growing unmet medical needs in liver diseases. GENFIT said the acquisition fits its strategic vision of becoming a global leader in ACLF (acute-on-chronic […]

September 19, 2022 - 4 minutesmins - By Jim Cornall

News and Trends 12 Sep 2022

Could combining biotech and photosynthetic cyanobacteria help the energy crisis?

A group of researchers in Switzerland is using photosynthetic bacteria to generate energy. After implanting nanotubes into them, the bacteria can create energy. And when the cells divide, those nanotubes stay with subsequent generations. While there’s a long way to go, and many questions to be answered, Ardemis Boghossian at EPFL’s School of Basic Sciences […]

September 12, 2022 - 6 minutesmins - By Jim Cornall

News and Trends 12 Sep 2022

Cuffless device worn 24/7 can lower blood pressure, says Aktiia

A company making cuffless monitors for blood pressure says a significant and sustained reduction has been achieved for patients wearing the monitor 24/7. The device, made by Aktiia, measures blood pressure at optimal times throughout the day and night and was used in a study on hypertensive patients using a data set of more than […]

September 12, 2022 - 2 minutesmins - By Liza Laws

News and Trends 8 Sep 2022

Cultivated Biosciences raises $1.5M to take fats to the next frontier

Cultivated Biosciences, an ingredient startup biotech company founded by Swiss entrepreneurs Tomas Turner and Dimitri Zogg, has just raised a $1.5M pre-seed round. The funding will enable the growing team to further optimize its production processes, research food applications and start product development of its creamy ingredient for dairy alternatives from non-GMO yeast with their […]

September 8, 2022 - 2 minutesmins - By Jim Cornall

In Depth 7 Sep 2022

The biggest private biotech investments in August 2022

The healthcare-focused companies Orna Therapeutics, F2G and Sironax bagged the biggest biotech investments in August 2022, with mRNA vaccines, genomics and fermentation technology attracting big funding rounds. As many took a well-deserved vacation in the month of August 2022, the world of biotech remained busy with fundraising. Sit back and browse our lists of the […]

September 7, 2022 - 3 minutesmins - By Jonathan Smith

News and Trends 1 Sep 2022

Labiotech adds conference and event listings

In the past few months, Labiotech.eu has boosted its coverage range to go global, added a podcast, expanded to three weekly newsletters, introduced special monthly newsletters, and now we’ve added another string to our bow – conference and event listings. The page is designed so visitors can easily jump between months and events. Listings have […]

September 1, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 31 Aug 2022

Researchers identify possible target for type of sporadic ALS

Researchers have published two papers describing how they identified a potential new pathway for treating a sporadic form of amyotrophic lateral sclerosis (ALS). The studies were published as part of a cooperative research agreement between the National Institute of Neurological Disorders and Stroke (NINDS), part of the National Institutes of Health, and the Swiss biotech […]

August 31, 2022 - 3 minutesmins - By Jim Cornall

Interview 31 Aug 2022

How CDMOs keep pace with trends in advanced therapies

Advanced therapies including cell and gene therapies are exploding in demand, but the manufacturing process can be difficult. Jean-Christophe Hyvert, president of biologics and cell & gene at the CDMO Lonza, sheds light on the latest trends in advanced therapies and how manufacturers are keeping up. In 2021, global funding going to cell and gene […]

August 31, 2022 - 8 minutesmins - By Jonathan Smith

News and Trends 29 Aug 2022

Marketing authorization granted for treatment of serious retinal diseases

The European Commission has granted marketing authorization to Ranivisio, a treatment for several serious retinal diseases. Polpharma Biologics Group BV, Formycon AG and their Swiss joint venture, Bioeq AG, announced the news today (August 29) that the authorization was granted to Ranivisio, which is a biosimilar to Lucentis, a ranibizumab injection. Positive opinion: CHMP The […]

August 29, 2022 - 3 minutesmins - By Liza Laws

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us